An inferior vena cava (IVC) filter is a small cage-like medical device that can be inserted by doctors to stop dangerous blood clots from traveling to the blood vessels of the lungs. Their structure allows them to catch fragments of clots that form in the legs or pelvis before these blockages run the risk of causing a pulmonary embolism (PE). These metal filters are surgically implanted in patients who cannot tolerate blood thinners or have seen little success with those drugs.
Bextra (valdecoxib), which was manufactured by Pfizer, belongs to a special class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) called Cox-2 inhibitors. It was primarily prescribed for osteoarthritis, rheumatoid arthritis, and dysmenorrheal until it was pulled from the market due to side effects.
The FDA based its decision on studies showing that Bextra puts patients at an increased risk of heart attack and stroke, and also higher risk of a serious skin reactions than if they take other Cox-2 inhibitors, and do not receive greater benefits.
The examination of Cox-2 inhibitors was sparked when Merck pulled Vioxx from the market because of an increased risk of cardiovascular events.
Celebrex and other NSAIDs now receive a black box warning, the FDA's strongest, describing the risks involved in taking the drug. In addition, the FDA will require Pfizer, the maker of Celebrex, to evaluate the risks of the drug with a long-term study.
Over-the-counter products that include NSAIDs, such as ibuprofen and naproxen, were allowed to stay on shelves, but manufacturers were forced to change their labels. The new labels will include information on the potential cardiovascular and intestinal risks as well as the possibility of rare but sometimes fatal skin reactions that can occur when taking the drugs.
If you or a loved one experienced serious or fatal side effects while taking Bextra, contact us today to determine if you may have a personal injury claim.